Figure 3. Change From Baseline in HDRS-17 Total Score (Post Hoc Analysis) in Patients Receiving Zuranolone 30 mg/d With (A) Baseline HDRS-17 Total Score ≥ 24, (B) Measurable Drug Levels, and (C) Baseline HDRS-17 Total Score ≥ 24 Plus Measurable Drug Levels

A. Patients With Baseline HDRS-17 Total Score ≥ 24

B. Patients With Measurable Drug Levels

C. Patients With Baseline HDRS-17 Total Score ≥ 24 Plus Measurable Drug Levels

*Model used was the mixed effects for repeated measures with treatment (zuranolone 30 mg, zuranolone 20 mg, or placebo), baseline HDRS-17 total score, SOC antidepressant use at baseline (Yes or No), assessment time point, and time point-by-treatment interaction as fixed effects with unstructured covariance structure. Secondary and post hoc analyses were not adjusted for multiplicity. Shaded area indicates 14-day treatment period.

†Model used was the mixed effects for repeated measures with treatment (zuranolone 30 mg, zuranolone 20 mg, or placebo), baseline HDRS-17 total score, SOC antidepressant use at baseline (Yes or No), assessment time point, and time point-by-treatment interaction as fixed effects with unstructured covariance structure. Secondary and post hoc analyses were not adjusted for multiplicity.

‡Model used was the mixed effects for repeated measures with treatment (zuranolone 30 mg, zuranolone 20 mg, or placebo), baseline HDRS-17 total score, SOC antidepressant use at baseline (Yes or No), assessment time point, and time point-by-treatment interaction as fixed effects with unstructured covariance structure. Secondary and post hoc analyses were not adjusted for multiplicity.

*P < .05 vs placebo. †P < .01 vs placebo. ‡P < .0025 vs placebo.

Abbreviations: HDRS-17 = 17-item Hamilton Depression Rating Scale total score, LSM = least-squares mean, n = number of patients on that day, SOC = standard of care.